Here's what could derail the thesis: Regulatory & Pricing Pressure Government price controls on GLP-1 drugs (Trump administration deal includes price cuts) Medicare/Medicaid coverage expansion requires discounting International pricing pressures as volumes increase Competition Intensifying Novo Nordisk fighting back with oral GLP-1 programs Amgen, Pfizer, and others entering the space Compounding pharmacies eating market share during supply shortages Operational Challenges Manufacturing constraints still limiting supply in some markets CVS formulary changes disrupted Zepbound access temporarily Volume growth partially offset by 10% lower realized prices in Q3 Valuation Risk At ~$930B market cap, expectations are sky-high Any guidance miss or pipeline disappointment will be punished severely Forward P/E of ~42 leaves little room for error Pipeline Execution Orforglipron approval timing uncertain Alzheimer's market adoption slower than hoped Clinical trial failures in crowded pipeline Smart investors acknowledge risks while staying focused on the long-term thesis

3 , 6 MMNST is often misdiagnosed due to its overlapping histological features with metastatic melanoma and other melanotic tumors, or it may radiographically mimic other nerve sheath tumors by exhibiting a dumbbell configuration along nerve roots
Need help optimizing your plan
And when we look at conventional treatments, not all of them, but some of them, we see effects
Heat and moisture exposure may reduce peptide stability over time
This is why our mission at TrimRx is to merge clinical expertise with empathetic, modern technology